Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer

We investigated the cardiovascular thrombotic risk after surgical castration (SC) versus gonadotropin-releasing hormone agonists (GnRHa) in Chinese men with prostate cancer. All Chinese prostate cancer patients who were treated with SC or GnRHa from year 2000 to 2009 were reviewed and compared. The...

Full description

Bibliographic Details
Main Authors:	Jeremy YC Teoh, Samson YS Chan, Peter KF Chiu, Darren MC Poon, Ho-Yuen Cheung, Simon SM Hou, Chi-Fai Ng
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-06-01
Series:	Asian Journal of Andrology
Subjects:	androgen deprivation therapy; Chinese population; cardiovascular events; myocardial infarction; prostate cancer; stroke
Online Access:	http://ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=3;spage=493;epage=496;aulast=Teoh

Similar Items

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

How do we define “castration” in men on androgen deprivation therapy?
by: Sarin Itty, et al.
Published: (2020-01-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth
by: Luo J, et al.
Published: (2020-09-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration
by: Kenichiro Ishii, et al.
Published: (2019-09-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
by: Jeremy YC Teoh, et al.
Published: (2017-01-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
by: Yong Jin Kang, et al.
Published: (2017-11-01)

Discordance between testosterone measurement methods in castrated prostate cancer patients
by: Mélanie Rouleau, et al.
Published: (2019-02-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
by: Matteo Capaia, et al.
Published: (2018-06-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Novel agents in the management of castration resistant prostate cancer
by: Shruti Chaturvedi, et al.
Published: (2014-01-01)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
by: Juan Morote, et al.
Published: (2017-10-01)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Melissa Gamat-Huber, et al.
Published: (2020-09-01)

The Effect of Castration on Peripheral Autonomic Neurons Supplying Mammalian Male Genitourinary System
by: Jerzy Kaleczyc, et al.
Published: (2021-07-01)

Diferelin® as an effective chemical castration agent for patients with prostate cancer
by: K. M. Nyushko, et al.
Published: (2021-02-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer
by: Tingmang Yan, et al.
Published: (2021-04-01)

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
by: Bum Sik Tae, et al.
Published: (2019-08-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Response to the gonadotropin releasing hormone agonist leuprolide in immature female sheep androgenized in utero
by: SERGIO E RECABARREN, et al.
Published: (2005-01-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?
by: Raghavendra Tejo Karthik Poluri, et al.
Published: (2018-06-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients
by: Shangqian Wang, et al.
Published: (2020-05-01)

Lacrimal sac adenocarcinoma managed with androgen deprivation
by: David H. Abramson, et al.
Published: (2020-09-01)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
by: Renée de Leeuw, et al.
Published: (2020-10-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
by: Herjan J.T. Coelingh Bennink, et al.
Published: (2021-06-01)

Phage display screening identifies a prostate specific antigen (PSA)–/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer
by: Yi Sui, et al.
Published: (2021-03-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis
by: Ann-Yae Na, et al.
Published: (2021-07-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Remission of Membranous Nephropathy after Treatment of Localised Prostate Cancer
by: Daniel Adlington, et al.
Published: (2019-06-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)